SkyAI, Inc. has amended its cash tender offer to include 100% purchase of all pre-funded and stapled warrants, extending the offer to all holders on equal terms. Bastion Trading Limited, a major stockholder, agreed to tender all its shares and warrants and entered a three-year standstill agreement, restricting its influence on the company. The offer now expires on November 12, 2026, with SkyAI prepared to pay approximately $214.3 million if all securities are tendered. This move aims to provide liquidity to warrant holders and facilitate an orderly process for the company’s securities.
SkyAI's recent tender offer update provides context for readers. For those tracking the Technology sector, here is Pluang's market snapshot as of Oct 28, 2026 02:21 WIB: Out of 150 priced US tech stocks, 83 rose and 67 fell. Notable movers include STM at USD 48.59 with a 7.51% increase and Pluang order activity showing 72% Sell, IONQ at USD 33.00 up 7.28% with 64% Sell activity, and FSLY at USD 27.44 rising 7.15% with 95% Sell activity.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
